Trial Profile
Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Carmustine (Primary) ; Cisplatin (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Obinutuzumab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms LyMa101
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2018 Status changed from not yet recruiting to recruiting.